Trials / Recruiting
RecruitingNCT06448793
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 55 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Approved Non-small Cell Lung Cancer (NSCLC) therapies | As prescribed by treating physician |
Timeline
- Start date
- 2024-11-25
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2024-06-07
- Last updated
- 2025-12-04
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06448793. Inclusion in this directory is not an endorsement.